Research dispatches.
Featured Compounds

Triple-receptor research: GLP-1, GIP, and glucagon agonism
Retatrutide (RT) occupies a distinct position in metabolic research literature. Where earlier GLP-1 analogs acted on a single receptor class, the triple-agonist design targets GLP-1, GIP, and glucagon receptors simultaneously – enabling study of parallel incretin pathways within a single experimental model.
Preclinical research has focused on the compound’s effects on energy homeostasis, glucose regulation, and adipose tissue signaling. The glucagon component distinguishes RT from dual-incretin analogs, adding a hepatic signaling dimension that continues to generate investigation.

